Ganglioside (GM1, GD1b, and GQ1b) Antibodies, IgG and IgM

Also known as: GM1 LIGHT

Clinical Use

Use

This test may have diagnostic relevance in conditions such as multifocal motor neuropathy (MMN), Guillain-Barré syndrome (GBS), and Miller Fisher syndrome (MFS). It is used for detecting antibodies against gangliosides GM1, GD1b, and GQ1b in IgG and IgM forms. Elevated antibody levels against ganglioside-monosialic acid (GM1) are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 antibodies may occur as IgM (polyclonal or monoclonal) or IgG type antibodies. These antibodies can be detected in patients with diverse autoimmune neuropathies and connective tissue diseases. They should be interpreted in conjunction with other clinical parameters to confirm disease as they are not standalone diagnostic tests.

Special Instructions

Not provided.

Limitations

Ganglioside antibodies may be present in normal individuals and should not be solely relied upon for diagnosis. This test was developed by ARUP Laboratories and has not been cleared or approved by the FDA. The performance characteristics of this laboratory-developed test (LDT) were determined by ARUP Laboratories. The test is intended for clinical purposes and should be used with other clinical assessments. Results should be interpreted in the context of the patient's clinical picture.

Test Details

New York Approved